TSX VENTURE EXCHANGE: AVI
QUEBEC CITY, May 26 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) today announced that Dr Charles
Doillon, M.D., Ph.D., Researcher at Centre de Recherche du Centre Hospitalier
de l'Université Laval, who is leading Advitech's wound healing program, will
be presenting a progress report on the Corporation's IM technological platform
for wound management at Gordon Research Conference ("GRC") on Tissue Repair
and Regeneration at Colby-Sawyer College, New London, NH, on Thursday June
For over 75 years, GRC's meetings have been recognized as the world's
premier scientific conferences, where leading investigators from around the
globe discuss their latest work and future challenges. Advitech's presentation
was accepted after a scientific peer reviewed evaluation.
"During this meeting, scientists around the world will have the
possibility to comment new data released on the IM fraction and its wound
healing properties. Also, we expect to use this meeting to introduce the IM
fraction to pharmaceutical companies" said Dr Doillon.
The progress report will present updated information which, in Advitech's
opinion, demonstrates that the IM fraction reduces scar formation and prevents
hypertrophic scarring. This bioactivity appears to be associated with the
presence of growth factors and peptides with immune modulatory properties as
well as antimicrobial activities.
In 2008, Advitech initiated an extensive R&D wound healing program to
characterize specific fractions and to obtain toxicological data through in
vitro and in vivo studies. Advitech intends to take advantage of the unique
bioactive properties of the IM fraction to launch a cosmeceutical product line
by the end of 2009.
ABOUT Dr CHARLES J. DOILLON, M.D., Ph.D.
A recipient of scientific and medical awards, Dr Doillon is currently a
full professor (Dept. Surgery) at Laval University, Quebec City, and
researcher at the Research Center of the Centre Hospitalier de l'Universite
Laval (CHUL). Dr Doillon has authored and co-authored several scientific
publications and communications in the fields of wound healing and collagen
remodeling, and was a pioneer by demonstrating a correlation between collagen
fiber distribution and biomechanics in wound tissues.
ABOUT WOUND HEALING:
According to Epsicom Business Intelligence Ltd., the global wound care
market totalled $7.2 billion in 2006, with a 10% growth rate. The market
growth is fueled by the population ageing, the increased incidence of diabetes
as well as the technological advancement and the introduction of more
efficient and cost-effective therapies compared to conventional treatments.
ABOUT ADVITECH INC. www.advitech.com:
Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Advitech produces Dermylex(R) for the treatment of
Advitech has initiated an innovative wound healing research program to
develop new applications for both its XP-828L and IM technological platforms.
This press release contains forward-looking statements, which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual results
could differ materially from those projected herein. The TSX Venture Exchange
does not accept responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Advitech Inc.: Renaud Beauchesne, MBA,
Executive Chairman, (418) 686-7498, ext. 228, firstname.lastname@example.org; Serge Comeau,
Investor's relations, (514) 862-4160, email@example.com